Sanofi, a global and diversified healthcare leader, and Bristol-Myers Squibb Company (BMS) reported that  Apotex has made payment in the amount of $442.21 million  to satisfy the damages ruling of the Plavix (clopidogrel bisulfate) patent infringement case against Apotex. This payment, which follows the decision of the US Court of Appeals for the Federal Circuit in October 2011 upholding the payment of damages to the companies by Apotex, represents the final phase of the Plavix patent litigation between the companies and Apotex, which was initiated in March 21, 2002.

Sanofi and Bristol-Myers Squibb were  also awarded  $1,258,682 in post-judgment interest and  $900,000 in costs in addition to the damages award.

Sanofi and Bristol-Myers Squibb are pleased that their intellectual property rights have been upheld and that Apotex has made reparation of the harm caused by the at-risk launch of a generic version of clopidogrel bisulfate in 2006.

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs.

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.